Literature DB >> 11830184

Both the shell of the nucleus accumbens and the central nucleus of the amygdala support amphetamine self-administration in rats.

Jessica Chevrette1, James R Stellar, Gary W Hesse, Athina Markou.   

Abstract

Intracranial self-administration of drugs offers the opportunity to localize the neuronal substrates mediating the rewarding effects of drugs. The purpose of the present study was to explore whether the nucleus accumbens shell and the central nucleus of the amygdala, two components of the "extended amygdala," would support self-administration of the psychostimulant amphetamine. Male Wistar rats were trained to lever press under a Fixed Ratio 1 schedule of reinforcement for D-amphetamine injections (0, 1.0, 1.5, 2.0 and 3.0 microg/microl/inj) into either the nucleus accumbens shell or the central nucleus of the amygdala. An ascending limb dose-response function with peak responding at the 2.0 microg/microl/inj dose was obtained for self-administration at both brain sites. These results indicate that monoaminergic transmission in both the nucleus accumbens shell and the central nucleus of the amygdala mediates the rewarding effects of amphetamine. Further, the present study provides additional evidence about the functional homogeneity of the forebrain continuum called the "extended amygdala."

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11830184     DOI: 10.1016/s0091-3057(01)00686-4

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  12 in total

Review 1.  Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits.

Authors:  J D Salamone; M Correa; A Farrar; S M Mingote
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

2.  Psychostimulants and forced swim stress interaction: how activation of the hypothalamic-pituitary-adrenal axis and stress-induced hyperglycemia are affected.

Authors:  Humberto Gagliano; Juan Antonio Ortega-Sanchez; Roser Nadal; Antonio Armario
Journal:  Psychopharmacology (Berl)       Date:  2017-07-14       Impact factor: 4.530

Review 3.  Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective.

Authors:  Antonio Alcaro; Robert Huber; Jaak Panksepp
Journal:  Brain Res Rev       Date:  2007-08-21

Review 4.  The neurocircuitry of addiction: an overview.

Authors:  M W Feltenstein; R E See
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

Review 5.  Systems level neuroplasticity in drug addiction.

Authors:  Matthew W Feltenstein; Ronald E See
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

6.  The contribution of the central nucleus of the amygdala to individual differences in amphetamine-induced hyperactivity.

Authors:  Mary E Cain; Rosemary A Coolon; Margaret J Gill
Journal:  Behav Brain Res       Date:  2009-03-19       Impact factor: 3.332

7.  Ethanol is self-administered into the nucleus accumbens shell, but not the core: evidence of genetic sensitivity.

Authors:  Eric A Engleman; Zheng-Ming Ding; Scott M Oster; Jamie E Toalston; Richard L Bell; James M Murphy; William J McBride; Zachary A Rodd
Journal:  Alcohol Clin Exp Res       Date:  2009-09-17       Impact factor: 3.455

Review 8.  Kicking the habit: the neural basis of ingrained behaviors in cocaine addiction.

Authors:  R Christopher Pierce; Louk J M J Vanderschuren
Journal:  Neurosci Biobehav Rev       Date:  2010-01-25       Impact factor: 8.989

9.  Differences in performance between Sprague-Dawley and Fischer 344 rats in positive reinforcement tasks.

Authors:  Jesse S Rodriguez; Sherin Y Boctor; Clyde F Phelix; Joe L Martinez
Journal:  Pharmacol Biochem Behav       Date:  2007-11-06       Impact factor: 3.533

10.  Individual differences in amphetamine self-administration: the role of the central nucleus of the amygdala.

Authors:  Mary E Cain; Emily D Denehy; Michael T Bardo
Journal:  Neuropsychopharmacology       Date:  2007-06-13       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.